Metastasis to the liver remains an important problem in the treatment of patients with gastrointestinal cancer. We examined the mechanism and effect on liver metastasis of in vivo interleukin -2 ( IL -2 ) gene transfer to the liver. RCN -9 cells derived from F344 rat colon adenocarcinoma were injected into syngeneic rats via the ileocecal vein to induce liver tumors. A total of 2.5Â10 9 pfu of adenovirus vector harboring the human IL -2 gene ( AdCMVhIL -2 ), or 2.5Â10 9 pfu of control vector encoding -galactosidase was administered before RCN -9 cell challenge. On day 14, mean tumor weight was 4.0 ± 2.4 g in the control group, whereas IL -2 -transduced livers had no tumors. Survival of AdCMVhIL -2 -treated rats was significantly longer than that of control rats ( P <.01 ). Flow cytometry demonstrated that the proportion of natural killer ( NK ) cells had increased among sinusoidal cells collected from IL -2 -transduced livers. These cells were highly cytotoxic to RCN -9 cells in vitro in the presence of a physiological high concentration of recombinant IL -2. Preventative effects of IL -2 transduction of the liver against liver metastasis were lost after depletion of NK cells by treatment with anti -asialo GM1 antibodies. Our results indicate that IL -2 gene transfer to the liver prevents liver metastasis by continuously providing physiological high concentrations of IL -2 in the liver, thereby activating sinusoidal NK cells. Cancer Gene Therapy ( 2002 ) 9, 655 -664 doi:10.1038/sj.cgt.7700483
T umor recurrence with liver metastasis sometimes occurs after surgical resection of primary colorectal carcinoma, despite no evidence of liver metastasis while in operation. These arise from handling of tumors or existence of micrometastasis during operation. Although localized solitary liver metastasis from colorectal carcinoma can be treated by surgical resection, multiple hepatic metastases cannot. 1 Both chemotherapy 2 and immunotherapy 3 have been used to treat multiple metastases to the liver, but currently available results are disappointing. Therefore, strategies designed to prevent liver metastasis in patients with no apparent metastasis at operation may hold the best promise of improving outcome.
Cytokines are biological response modifiers widely used for locoregional or systemic immunotherapy in patients with cancer. Interleukin-2 (IL -2 ) is known to play a major role in activation, differentiation, and growth of hematopoietic cells, particularly T lymphocytes and natural killer (NK ) cells. 4, 5 Recombinant human IL -2 (rIL -2 ) has been used for cancer immunotherapy for a number of years, 6 but has several drawbacks. Because IL -2 undergoes rapid tissue clearance, high concentrations are difficult to maintain in target organs, such as the liver, after systemic administration. Treatment with high doses of IL -2 can cause severe side effects, including chills, fever, headache, and capillary leak syndrome, and the dose of IL -2 must be decreased, negatively affecting outcome. 7, 8 To overcome these problems, transduction of the IL -2 gene in the liver to produce a high local concentration of IL-2 may be an effective strategy for enhancing antitumor activity without increasing side effects.
Present strategies for cytokine -based gene therapy of cancer involve ex vivo transduction of the GM -CSF, 9, 10 IL -2, 11,12 B7, 13 or other genes into autologous tumor cells. After gene transduction, the cells are returned to the body -a process referred to as vaccination 14 -or genes harboring vectors are directly injected into the tumor in vivo. 15, 16 The former technique is complex, and autologous tumor cells obtained at operation must be cultured for a while after gene transduction. Consequently, vaccination cannot be performed at the time of operation. It also carries the risk of implanting viable cancer cells. The vector injection technique requires that the tumor is macroscopically defined and cannot be done in patients who have micrometastasis because vectors cannot be directly injected into the tumor.
When used to treat cancer, suicidal genes such as HSV-TK, 17 or tumor suppressor genes such as p53 18 must be transduced directly and securely into only tumor cells. With cytokines, however, cytokine gene transduction in tissue around tumor cells might create a cytokine -rich microenvironment, permitting gene therapy to treat tumors associated with micrometastasis or multiple metastases.
On the basis of this hypothesis, we injected adenovirus vector via the portal vein to promote efficient gene transduction and expression of IL -2 in the liver, thereby creating a IL -2-rich microenvironment in the liver. Because complicated procedures are not required, this technique can be done at the time of operation. We analyzed the preventive efficacy and toxicity of this in vivo IL -2 gene therapy system in a rat model of liver metastasis, using an adenovirus vector carrying the human IL -2 gene, and explored the mechanism of action.
Materials and methods

Animals and cell lines
Specific pathogen -free 6 -week -old male F344 /DuCrj rats were purchased from Charles River (Atsugi, Japan ). All animals were supplied rat food and water ad libitum. They were housed in accordance with the criteria outlined in the Guide for the Care and Use of Laboratory Animals, prepared by the National Academy of Science.
The RCN -9 cell line 19 derived from a 1,2-dimethylhydrazine-induced colon adenocarcinoma in an F344 /DuCrj rat and NK -sensitive Moloney virus -induced YAC -1 lymphoma cell line were purchased from Riken Cell Bank ( Ibaragi, Japan ). These cell lines were cultured in RPMI-1640 (Nissui Pharmaceutical, Tokyo, Japan ) supplemented with 10% inactivated fetal bovine serum (Intergen, Purchase, NY ) and 1% penicillin -streptomycin (Gibco BRL, Grand Island, NY ) at 378C in a humid atmosphere of 5% CO 2 . The RCN -9 cell line did not express major histocompatibility complex class I or II, as confirmed by flow cytometry, and was injected in 1 mL of phosphatebuffered saline (PBS ) in vivo.
Adenovirus vectors
E1 -and E3 -defective adenovirus vectors carrying the human IL -2 gene ( AdCMVhIL -2 ) or the Escherichia coli -galactosidase gene (AdCMVLacZ ) under the control of the cytomegalovirus promoter were kindly provided by Atsushi Miyanohara ( UCSD Program Human Gene Therapy, La Jolla, CA ). 20 Virus stocks were propagated in 293 cells. The viral preparations were purified by double CsCl density ultracentrifugation, dialyzed, and stored in PBS with 10% glycerol at À 708C. The titers of the viral stocks were determined by plaque assay using 293 cells. 21, 22 All vectors were injected in 0.2 mL of PBS.
Experimental design
F344 /DuCrj rats were anesthesized with diethyl ether. A ventral midline incision was made to expose the ileocecal vein, a branch of the portal vein.
Establishment and evaluation of model of hepatic metastasis from colon carcinoma Rats were given an intraportal injection of 8Â10 5 , 8Â10 6 , or 8Â10 7 RCN -9 cells and were sacrificed after 14 days to count tumor nodules in the liver. Because the number of nodules on the liver surface did not consistently represent the degree of metastasis, the liver was mashed to find and count hard nodules 1 mm or more in diameter.
Determination of amount of adenovirus vector delivered via ileocecal vein
To confirm the maximum safe dose of AdCMVhIL -2, 1.0Â10 9 , 2.5Â10 9 , or 5.0Â10 9 pfu of AdCMVhIL -2 or AdCMVLacZ was injected into the ileocecal vein of rats. Survival and toxicity were evaluated daily.
Treatment with AdCMVhIL -2
The adenovirus vectors were injected with 0.2 mL of PBS containing 2.5Â10 9 pfu of AdCMVhIL-2 or AdCMVLacZ into the ileocecal vein.
mRNA level. The livers of rats treated with AdCMVLacZ or AdCMVhIL -2 were partially dissected on days 3, 7, 14, 21, and 28. They were immediately flash-frozen in liquid nitrogen and stored at À 708C. 23 We performed reverse transcription polymerase chain reaction ( RT-PCR ) analysis to analyze human IL -2 mRNA. 
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Assay of human IL -2 serum level. Blood was drawn from the inferior vena cava of the rats on day 3 after adenovirus injection and centrifuged. The serum was collected and stored at À 808C. IL -2 concentration was measured with the use of a commercial ELISA kit specific for human IL -2 ( Biosource International, Camarillo, CA ).
Prophylactic effect of AdCMVhIL -2 on liver metastasis A total of 2.5Â10 9 pfu of AdCMVhIL -2 was injected into the ileocecal vein; 8Â10 6 RCN -9 cells was then similarly injected ( group I). As control, 2.5Â10 9 pfu of AdCMVLacZ ( group II ) or 0.2 mL of PBS (group III ) was injected instead of AdCMVhIL -2, followed by 8Â10 6 RCN -9 cells. Some of the rats in each group were randomly sacrificed on day 14, and the liver tumors were counted and weighed. Survival was evaluated daily in the other rats. Autopsy was performed in all rats.
Estimation of effector cells inducing prophylaxis against liver metastasis Surface markers and cytotoxicity of sinusoidal cells were examined to determine potential effector cells.
Isolation of sinusoidal mononuclear cells in the liver and immunophenotypic analysis. Rats in groups I, II, or III were sacrificed on day 3 after treatment. Sinusoidal cells were isolated by sinusoidal lavage as described by Bouwens et al. 24 Briefly, the portal vein and inferior vena cava were cannulated with 18 -and 16 -gauge catheters, respectively. The tip of the catheter inserted into the inferior vena cava was placed at the level of the communication with the hepatic veins. The inferior vena cava was then clamped off at both the cranial level of the communication with the hepatic veins and the cranial level of the communication with the renal veins. The liver was perfused with warm (378C) Dulbecco's PBS without Ca 2 + and Mg 2 + , supplemented with 0.1% ethylenediaminetetraacetic acid ( EDTA ), at pH 7.4 via the portal vein. The perfusion pressure was raised to 50 cm H 2 0, and 300 mL of perfusate was collected from the hepatic veins ( Fig 1) . After the cells in the collected perfusate were spun at 300Âg for 10 minutes, they were resuspended in 4 mL of PBS and carefully layered on 3 mL of Ficoll-Hypaque ( density, 1.077 g /mL; Lymphoprep, Nycomed Pharma, Oslo, Norway ). After centrifugation for 30 min at 400Âg, the interface containing mononuclear cells was collected and washed in PBS. The cells were counted in a cell chamber.
The surface phenotypes of the sinusoidal mononuclear cells were identified with the use of FITC -conjugated monoclonal antibodies (mAbs ). The used mAbs were FITC anti-rat CD3, FITC anti -rat PanBm, and FITC anti -rat CD11b /c, all purchased from CALTAG (Burlingame, CA ), and FITC anti -rat NKR -P1A was purchased from Pharmingen (San Diego, CA ). The presence of fluorescence -positive cells was analyzed by FACS Calibur (Becton Dickinson, Mountain View, CA ).
Purification of sinusoidal NK cells. To further purify NK cells, the sinusoidal mononuclear cells were filtered through a nylon wool column, and were then transferred to plastic dishes to remove monocytes. The nonadherent cells were centrifuged on a 45% Percoll ( Sigma, St. Louis, MO ) gradient at 550Âg for 25 minutes to obtain NK -enriched sinusoidal mononuclear cells at the top of the gradient. 24 The NK -enriched sinusoidal mononuclear cells were collected, and their cytotoxicity was evaluated by 51 Cr release assay. The expression of CD25 on NK cells was identified by twocolor flow cytometry with FITC anti -rat NKR -P1A and PE anti-rat CD25 ( Pharmingen ). Rats were treated with various concentrations of AdCMVhIL -2 or AdCMVLacZ via the ileocecal vein. Six rats given 1.0Â10 9 pfu of AdCMVhIL -2 remained healthy for 14 days after injection, whereas all rats given 2.5Â10 9 pfu or more of AdCMVhIL -2 had diarrhea by day 4. Two of the six rats given 5.0Â10 9 pfu of AdCMVhIL -2 died of severe diarrhea within day 4. Six rats given 5.0Â10 9 pfu of AdCMVLacZ remained healthy for 14 days after injection. Figure 2 The expression of human IL -2 mRNA in liver after gene transfer with adenovirus vector. Rats were treated with 0.2 mL of PBS containing 2.5Â10 9 pfu of AdCMVhIL -2 or AdCMVLacZ via the ileocecal vein. RT -PCR was performed on mRNA isolated from liver on days 3, 7, 14, 21, and 28 after injection. 4 33.6 ± 10.7
Rats were treated with various concentrations of AdCMVhIL -2 or AdCMVLacZ via the portal vein. Serum was collected from the inferior vena cava on day 3 after administration, and the serum level of rIL -2 was measured with a commercial ELISA kit specific for human IL -2. All data are expressed as mean ± SEM for four rats per group.
Confirmation of effector cells
Systemic injection of anti -asialo GM1 ( AGM1 ) in rats can devitalize the activity of NK cells. Rats were divided into two groups. One was given 250 g of anti -AGM1 rabbit serum ( Wako, Osaka, Japan ), injected intravenously on days À 3, 0, 3, 6, 9, and 12 after grouping to deplete NK cells. 25 -27 The other group was not given AGM1. Both groups were given AdCMVhIL -2 followed by RCN -9 tumor cells on day 0. The survival rates of the two groups were compared.
RNA preparation, reverse transcription, and subsequent PCR study Total RNA was isolated from the frozen tissue with the use of ISOGEN reagent (Nippon Gene, Tokyo, Japan ), following the manufacturer's protocol, 28 and first-strand cDNA was synthesized from 2 g of the RNA. Briefly, the RNA was incubated with either 50 pmol of oligo-dT primers or 200 pmol of random primers at 708C for 10 minutes and was reverse -transcribed with the use of SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA ) at 428C for 30 minutes. The reaction was terminated by heating at 708C for 15 minutes.
Two microliters of the reaction mixture was used as a template for PCR, which was performed in the presence of 20 M specific primers and 2.5 U of ExTaq DNA Polymerase (Takara Shuzo, Otsu, Shiga, Japan ). Primers for amplification of a 275-bp DNA fragment of human IL -2 cDNA were 5 0 -CAGCTACAACTGGAGCATTTAC -3 0 and 5 0 -CTTGATTTCCCTAGACTTTGT-3 0 . Primers for amplification of a 250 -bp fragment of rat -actin cDNA were 5 0 -TGGAGAAGATTTGGCACCAC -3 0 and 5 0 -ATGGGC-ACAGTGTGGGTGAC -3 0 . PCR was carried out according to the following protocol: 1 cycle at 948C for 10 minutes, 30 cycles of 1 minute at 948C, 1 minute at 558C, and 3 minutes at 728C, and then the last cycle at 728C for 15 minutes. PCR products were analyzed by electrophoresis on 2% agarose gel with a 100 -bp ladder marker (Invitrogen ).
Cytotoxicity assay 51 Cr release cytotoxicity assay was performed as described by Nagashima et al. 29 Briefly, target cells were labeled with 100
Ci of 51 Cr ( NEZ; 5 Ci/ mM ) at 378C for 1 hour. Washed target cells were mixed and incubated with effector cells at E:T ratios ranging from 20:1 to 2.5:1 in round -bottomed 96-well plates (FALCON 3077; Becton Dickinson Labware, Franklin Lakes, NJ ). Assays were always performed in triplicate. The cell mixtures were incubated for 4 or 18 hours with or without 75 pg /mL rIL -2 at 378C in a 5% CO 2 atmosphere. Spontaneous release and maximal release were determined by incubating target cells in medium alone or in 5% Triton X -100, respectively. After incubation, radioactivity was counted in a gamma counter (Auto well Gamma system ARC -600; ALOKA, Tokyo, Japan ), and the percentage of specific lysis was determined according to the following formula: % specific lysis =mean cpm experimental release À mean cpm spontaneous release /mean cpm maximal release À mean cpm spontaneous releaseÂ100.
Statistical analysis
Animal survival was compared on the basis of Kaplan -Meier estimates. Statistical significance was determined by the logrank test. Liver tumor numbers and weight were compared by the Mann -Whitney U test. NS, not significant ( P >.05 ) versus grade III. Rats were treated with PBS containing vector or not and were then given 8Â10 6 RCN -9 cells via the ileocecal vein. All rats given AdCMVLacZ ( group II ) or PBS ( group III ) had multiple tumor nodules in the liver on day 14 after injection of RCN -9 cells. In contrast, none of the eight rats treated with AdCMVhIL -2 ( group I ) had detectable tumor nodules on day 14. *P < .01 versus the other two groups for Mann -Whitney U test. 
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Antitumor immunity of sinusoidal NK cells activated with AdIL -2 H Tanji et al Figure 4 Phenotype analysis of sinusoidal mononuclear cells from rat liver. Sinusoidal mononuclear cells of the rats in groups I, II, or III were collected by sinusoidal lavage on postinjection day 3. Cell phenotype was analyzed by flow cytometry using specific monoclonal antibodies ( CD3, PanB, NKR -P1A, CD11b / c ) to clarify cell populations. a, d, g, j, m: Group III ( PBS ). b, e, h, k, n: Group II ( AdCMVLacZ ). c, f, i, l, o: Group I ( AdCMVhIL -2 ).
Results
Establishment of hepatic metastasis model from colon carcinoma
Rats given 8Â10 6 RCN -9 cells carried from six to more than 1000 liver tumors, whereas those given 8Â10 5 RCN -9 cells had no tumors on day 14. All five rats given 8Â10 7 RCN -9 cells died on the next day, possibly because of tumor embolism of the portal vein. We therefore used 8Â10 6 RCN -9 cells for treatment to permit rats with liver tumors to survive for 14 days.
Determination of dose of AdCMVhIL -2
Rats were given 1.0Â10 9 , 2.5Â10 9 , or 5.0Â10 9 pfu of AdCMVhIL-2 via the ileocecal vein. As control, 5.0Â10 9 pfu of AdCMVLacZ was administered instead of AdCMVhIL -2 ( Table 1 ). Six rats given 1.0Â10 9 pfu of AdCMVhIL -2 remained healthy for 14 days after injection, whereas all rats given 2.5Â10 9 pfu or more of AdCMVhIL -2 had diarrhea by day 4. Rats given 5.0Â10 9 pfu of AdCMVhIL -2 had a wasted appearance, with ruffled fur, tremors, and severe diarrhea. Two of the six rats given 5.0Â10 9 pfu of AdCMVhIL-2 died within 4 days after injection of AdCMVhIL-2; splenomegaly was found at necropsy. This toxicity was probably due to high concentrations of IL -2 because no rat died after treatment with 5.0Â10 9 pfu of AdCMVLacZ. To evaluate the prophylactic effect of AdCMVhIL-2 against liver metastasis, AdCMVhIL -2 was injected into rats at a dose of 2.5Â10 9 pfu.
Expression of hIL -2 gene and protein in liver
To analyze human IL-2 mRNA derived from adenovirus vectors in the liver, we performed RT-PCR analysis. Analysis of liver transduced with AdCMVhIL -2 clearly showed the presence of human IL-2 mRNA on days 3, 7, 14, and 21 days after transduction. In control rats treated with AdCMVLacZ or PBS, no human IL -2 mRNA was detected ( Fig 2 ) . Next, to verify successful production of hIL -2 in AdCMVhIL-2 -infected liver, hIL -2 was measured in serum on day 3 after adenovirus injection. As shown in Table 2 , the increase in hIL -2 level was proportional to the injected dose of AdCMVhIL -2. Successful transduction of the liver by intraportal injection of adenovirus vector was thus confirmed at the protein level in vivo. A low level of hIL -2 was also detected in AdCMVLacZ -treated rats, perhaps because of cross -reactivity with other rat cytokines. These results indicated that adenovirus -mediated gene transfer into the liver enables efficient production of the recombinant protein. In our model, the level of hIL-2 in the liver was estimated to be at least 75 pg /mL on day 3 after AdCMVhIL-2 administration.
Prevention of liver metastasis by AdCMVhIL -2
Prophylactic effects against liver metastasis were studied after hIL -2 gene transfer to the liver. Table 3 shows the number of nodules formed in the liver and the total weight of all tumors on day 14 in groups I, II, and III. None of the eight rats given AdCMVhIL -2 (group I ) carried detectable tumor nodules on day 14 after injection of RCN -9 cells. In contrast, all rats given AdCMVLacZ ( group II ) or PBS ( group III ) had from 12 to more than 1000 tumor nodules (total tumor weight, 4.0± 2.4 and 4.6 ±1.0 g, respectively ) in the liver on day 14 after injection of RCN -9 cells.
To examine the outcome of the hosts, the survival curves were compared among groups I, II, and III ( Fig 3) . Survival in group I was significantly longer than that in group II or III ( P <.01). Two of the six rats in group I died despite AdCMVhIL -2 treatment. The cause of death in these two rats was ascribed to multiple metastasis to the lung with bloody pleural effusion, but there was no evidence of liver metastasis in either rat. These results indicate that intraportal treatment with AdCMVhIL -2 protected the host rats from liver metastasis.
Numbers and subsets of sinusoidal mononuclear cells
Sinusoidal mononuclear cells were collected by sinusoidal lavage on day 3 after treatment and were counted in each group. The average number of sinusoidal mononuclear cells was 1.64Â10 7 cells in group I, 1.07Â10 7 cells in group II, and 0.71Â10 7 cells in group III. The number of sinusoidal mononuclear cells was clearly higher in group I than in the other two groups. To clarify the types of sinusoidal mononuclear cells, the percentages of CD3 + , PanB + , NKR -P1A + , and CD11b /c + cells in hepatic sinusoids were analyzed by one -color flow cytometry ( Fig 4 ) . The percentages of CD3 + , PanB + , and CD11b /c + cells in groups I, II, and III did not differ significantly. The percentage of NKR -P1A + cells in group I ( 50.6% ) was significantly higher than those in groups II ( 34.1% ) and III ( 34.5% ). On the basis of the numbers and phenotypes of sinusoidal cells, the absolute number of NK cells had increased in rats given AdCMVhIL -2. Because NK cells in sinusoidal cells increased, we further evaluated sinusoidal NK cells.
After the sinusoidal NK cells were enriched with Percoll, surface expression of CD25 (IL -2R ) was investigated. The NK -enriched sinusoidal cells in group I expressed little CD25 on their cell surface as compared with such cells in the other groups.
Cytolytic activity of sinusoidal NK cells activated by AdCMVhIL -2
To evaluate the cytotoxicity of increased sinusoidal NK cells after in vivo human IL -2 gene transfer, we performed 51 Cr Figure 5 Cytotoxicity of NK -enriched sinusoidal cells without rIL -2 ( A ) and with rIL -2 ( B ). Sinusoidal cells were isolated from the rats in group I ( AdCMVhIL -2 ), II ( AdCMVLacZ ), or III ( PBS ) on day 3 after treatment. After adherent cells were eliminated, the sinusoidal NK cells were purified with Percoll. NK -enriched sinusoidal cells were used as effectors. YAC -1 cells or RCN -9 cells were used as targets. A: A 4 -or 18 -hour 51 Cr release assay was done without rIL -2. B: A 4 -or 18 -hour 51 Cr release assay was done with 75 pg / mL rIL -2. Data are given as the mean ± SD of three independent experiments.
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Antitumor immunity of sinusoidal NK cells activated with AdIL -2 H Tanji et al release assay. Sinusoidal cells were isolated by sinusoidal lavage in each group on day 3 after injection of adenovirus vector and RCN -9 cells. After adherent cells were eliminated, the sinusoidal NK cells were purified with Percoll. The NK -enriched sinusoidal cells were used as effector. NK -sensitive YAC -1 cells and syngeneic RCN -9 cells served as targets. When cytotoxicity assay was carried out without rIL -2, the cytotoxicity of NK -enriched sinusoidal cells to YAC -1 in group I was significantly higher than that in group II or III on 4-or 18-hour 51 Cr release assay. However, cytotoxicity to RCN -9 was not detected in any group on 4 -or 18-hour 51 Cr-releasing assay without rIL -2 ( Fig 5A ) . NK killing activity was augmented by AdCMVhIL-2 transduction in the liver, but cytotoxicity to RCN -9, which was the target cell in vivo, was not detected without rIL -2. On the basis of Table 2 , the concentration of hIL -2 in the liver was presumed to be at least 75 pg/ mL. We therefore analyzed cytotoxicity at a concentration of 75 pg /mL rIL -2. When 51 Cr release assay was done with 75 pg/ mL rIL -2, the sinusoidal NK cells of rats in group I became able to lyse RCN -9 cells, weakly in 4-hour assay, and strongly in 18 -hour assay. In the control group, cytotoxicity to RCN -9 cells was not detected, even after the addition of rIL -2 ( Fig 5B ) . These results indicate that sinusoidal NK cells of rats given AdCMVhIL -2 were activated strongly and able to kill syngeneic target cells because gene transfer maintained a level of 75 pg /mL IL -2 in the liver.
Effect of inhibition of NK activity by systemic administration of anti-AGM1
To confirm if NK cells were responsible for the prophylactic effect against liver metastasis, NK cells were depleted with anti -AGM1 before and after injection of AdCMVhIL-2 followed by RCN -9 tumor cells. Figure 6 shows that survival in the group treated with anti -AGM1 was shorter than that in the group without anti -AGM1. The prophylactic effect of AdCMVhIL -2 was lost when NK cells were depleted for about 20 days. This result indicated that NK cells were responsible for preventing liver metastasis.
Discussion
Instead of intratumoral injection of adenovirus vector or tumor inoculation with transduced genes, we perform cytokine gene therapy for cancer by intraportal injection of vector. This study demonstrated that intraportal administration of AdCMVhIL -2 protected rats from liver metastasis by producing a physiological high concentration of IL -2 in the liver, thereby activating sinusoidal NK cells.
We chose an adenovirus vector because it has high affinity for the liver and promotes high levels of transgene expression. 30, 31 One limitation of adenovirus vector is that the transduced gene is excluded within a short time. In our experiment, the liver metastasis was prevented, although the duration of hIL -2 gene expression was within 1 month. In this regard, the adenovirus vector was apparently well suited for this series of experiments.
Although the toxicity of adenovirus vector in animals was recently studied, 32 there was no mortality in rats given AdCMVLacZ in this study. In our previous study, 33 1.0Â10
10 pfu of AdCMVIL -10 or AdCMVLacZ did not cause severe toxic effects in rats. Our present and previous studies indicate that a dose of 5.0Â10
9 pfu of adenovirus vectors causes no severe toxicity in rats.
As for IL -2 cytokine therapy, Toloza et al 34 directly injected adenovirus vector carrying the viral IL -2 ( AdvIL -2) into tumors and reported that the therapeutic usefulness of AdvIL -2 is restricted by the side effects due to synthesized IL -2 protein. Our results also show that the therapeutic window of AdCMVhIL -2 is narrow, but there is obviously a therapeutic dose without severe side effects.
Prevention of liver metastasis in this paper may result from direct toxicity of adenovirus vector to the tumor cells. RCN -9 cells were directly damaged in vitro after treatment with 100 MOI of adenovirus vector ( unpublished data ). However, the notion that adenovirus vector directly prevents liver metastasis seems unlikely because ( a) RCN -9 was inoculated to the rats after AdCMVhIL -2 administration, and adenovirus vector therefore could not directly infect RCN -9 cells; and (b ) similar doses of AdCMVLacZ did not prevent liver metastasis. These results indicate that prevention against liver metastasis did not result from the adenovirus vector itself, but from transduction of the hIL -2 gene.
To further elucidate the mechanism of the preventive effect of hIL-2 on liver metastasis, immunocompetent cells in the hepatic sinusoids were examined. In addition to increased number of sinusoidal NK cells in the rats given AdCMVhIL -2, treatment with an anti -AGM1 antibody abolished the preventive effect of AdCMVhIL -2. RCN -9 did not express major histocompatibility complex class I or II antigens. Bouwens et al 35 and Geerts et al 36 demonstrated that hepatic NK cells prevented liver metastasis as the first line in rats. Divino et al 37 and Pham -Nguyen et al 38 also reported that NK cells mediated immunological antitumor effects initiated by IL -12 gene therapy in a metastatic liver tumor model in the rat. Furthermore, Lukomska et al 39 reported that NK cell cytotoxicity was higher in liver sinusoids than in other organs in rats. Our Figure 6 Effect of NK cell depletion with anti -AGM1 on the survival of AdCMVhIL -2 treated rats. Sinusoidal NK cells were depleted with anti -AGM1 before injection of AdCMVhIL -2 followed by RCN -9 tumor cells.
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To elucidate the mechanism responsible for augmenting the killing activity of NK cells, the cytotoxicity of purified sinusoidal NK cells to RCN -9, a syngeneic target cell line, or YAC1, a NK -sensitive target cell line, was studied. Cytotoxicity, especially that against RCN -9 cells, was higher in the AdCMVhIL -2-treated group than in the control groups. The concentration of rIL -2 required to induce LAK activity is 1600 -35000 pg/ mL in vitro and killing is mediated without IL -2. 40, 41 However, the concentration of hIL -2 in our model was 75 pg /mL, a level much lower than that needed to induce LAK activity in vitro. The addition of 75 pg /mL rIL -2 was also required to mediate killing activity to RCN -9 cells in our model. These results indicate that the mechanism of antitumor effect by activated NK cells in our model differs from that of LAK activity induction in vitro. A concentration of 50 -100 pg /mL IL -2 is considered a physiological high concentration. 42 This concentration of IL -2 induces lymphocytes proliferation in response to alloantigens 43 but does not induce LAK activity in vitro. 42 Our findings indicate that NK cells in the AdCMVhIL-2 -treated rats had already been activated by IL -2 in vivo. Takeshita et al 44 studied immunomodulation in response to low concentrations of IL -2. Although resting NK cells lack IL -2 receptors, IL -2 stimulation induces IL -2 receptor expression. When IL-2, , and receptors are all expressed on cells, these three receptors form highaffinity receptors capable of reacting with even low concentrations of IL -2. Therefore, the sinusoidal NK cells of the rats given AdCMVhIL -2 most likely had highaffinity IL -2 receptors. However, increased numbers of IL-2R (CD25 )-positive NK cells in rats given AdCMVhIL -2 unfortunately could not be demonstrated by flow cytometry in the present study. This result refutes the notion that highaffinity IL-2 receptors of sinusoidal NK cells in group I might respond to 75 pg /mL rIL -2.
Nissen et al 42 found that mouse spleen NK cells cultured in the presence of physiological high IL -2 concentrations for 5 days in vitro acquired cytotoxic activity to syngeneic or allogeneic target cells. Their characteristics differed from those of NK cells activated in the presence of high IL -2 concentrations of about 1600 pg /mL. In our experiments, we collected sinusoidal NK cells from the rats on day 3 after adenovirus vector administration and cultured them for another 18 hours with rIL -2. Therefore, sinusoidal NK cells in group I were cultured for 4 days with what were apparently physiological high concentrations of IL-2. On the basis of the IL -2 concentration and culture period, NK cells in group I resembled activated mouse spleen NK cells as described by Nissen et al. Although the mechanism of NK cell activation in this model remains to be defined, our results suggest that treatment with AdCMVhIL-2 might clinically prevent liver metastasis derived from tumor cells spread through the portal vein during surgery or from undetected micrometastasis. Such prevention of metastasis could theoretically improve outcome in cancer of the digestive tract, including the colon, stomach, and pancreas. Our technique holds the promise of preventing liver metastasis with minimal side effects and is likely to contribute to the development of basic guidelines on gene therapy with cytokines.
